Physician profile
Wayne A Chieppa
NPI 1245230184
$491.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $196 · 2021: $107 · 2022: $26.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $237.70 | 2019-2022 | |
| Bioventus LLC | $68.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.37 | 2019 | |
| Sebela Pharmaceuticals INC. | $29.41 | 2019-2020 | |
| Integra Lifesciences Corporation | $26.12 | 2019 | |
| Heron Therapeutics, INC. | $22.89 | 2021 | |
| Grt US Holding, INC. | $17.27 | 2021 | |
| Nabriva Therapeutics, Plc | $14.00 | 2020 | |
| Zyla Life Sciences, INC. | $13.16 | 2020 | |
| Melinta Therapeutics, LLC | $12.68 | 2019 | |
| Smith+Nephew, INC. | $12.43 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Chieppa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.